{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T03:00:55Z","timestamp":1760151655990,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) showed effects in some hyperproliferative dermatologic pathologies. The aim of the study is the assessment of anti-psoriasis effect of diclofenac and celecoxib using a mice tail model. The topical application of substances on the proximal mice tails was performed for two weeks. The effects on the epidermal granular layer and mean epidermal thickness (excluding the stratum corneum) were evaluated using hematoxylin\u2013eosin staining. Orthokeratosis degree and percentual drug activity were calculated. A positive control group treated with tretinoin and two negative controls (white soft paraffin and untreated mice) were used. Orthokeratosis degree significantly increased in all the NSAIDs groups (celecoxib 1%, 2% and diclofenac 1%, 2%) and in the tretinoin 0.05% group, versus negative controls. Celecoxib 1% and 2%, tretinoin 0.05% and white soft paraffin significantly increased mean epidermal thickness, versus untreated mice. The values obtained in the case of celecoxib 2% ointment regarding the orthokeratosis degree and percentual drug activity are providing premises for further investigations regarding this effect and the mechanisms of action involved. Celecoxib 2% had the greatest percentual drug activity and is a promising substance for the anti-psoriasis topical treatment. Along with the COX-2 inhibition, celecoxib might have an anti-psoriasis effect by other independent mechanisms.<\/jats:p>","DOI":"10.3390\/pharmaceutics14040885","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T02:39:31Z","timestamp":1650335971000},"page":"885","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-Psoriasis Effect of Diclofenac and Celecoxib Using the Tail Model for Psoriasis"],"prefix":"10.3390","volume":"14","author":[{"given":"Diana Ana-Maria","family":"Ni\u021bescu","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-1974","authenticated-orcid":false,"given":"Horia","family":"P\u0103unescu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina Elena","family":"\u0218tefan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Veterinary Medicine, University of Agronomical Sciences and Veterinary Medicine, 011464 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren\u021biu","family":"Coman","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corneliu Cristian","family":"Georgescu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Dental Medicine, Craiova University of Medicine and Pharmacy, 200349 Craiova, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei Constantin","family":"Stoian","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gologan","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Applied Chemistry and Materials Science, Polytechnic University of Bucharest, 060042 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Fulga","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana Andreia","family":"Coman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Amoruso, G.F., Nistic\u00f2, S.P., Iannone, L., Russo, E., Rago, G., Patruno, C., and Bennardo, L. (2021). Ixekizumab May Improve Renal Function in Psoriasis. Healthcare, 9.","DOI":"10.3390\/healthcare9050543"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e14504","DOI":"10.1111\/dth.14504","article-title":"Emerging Role of anti-IL23 in the Treatment of Psoriasis: When Humanized Is Very Promising","volume":"33","author":"Dattola","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dastoli, S., Nistic\u00f2, S.P., Morrone, P., Patruno, C., Leo, A., Citraro, R., Gallelli, L., Russo, E., De Sarro, G., and Bennardo, L. (2022). Colchicine in Managing Skin Conditions: A Systematic Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020294"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1468-3083.2005.01198.x","article-title":"Recommendations for the Topical Treatment of Psoriasis","volume":"19","author":"Kragballe","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3892\/etm.2021.10403","article-title":"Experimental Research in Topical Psoriasis Therapy (Review)","volume":"22","author":"Costescu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/CCID.S160697","article-title":"Are Quantitative Histopathologic Criteria Capable of Differentiating Psoriasis from Chronic Dermatitis?","volume":"11","author":"Basir","year":"2018","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaad.2017.01.005","article-title":"The Histopathological Differentiation between Palmar Psoriasis and Hand Eczema: A Retrospective Review of 96 Cases","volume":"77","author":"Park","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/01913123.2014.952470","article-title":"Nuclear Factor Kappa B and Cyclo-Oxygenase-2: Two Concordant Players in Psoriasis Pathogenesis","volume":"39","author":"Bakry","year":"2015","journal-title":"Ultrastruct. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e12800","DOI":"10.1111\/dth.12800","article-title":"Treatment of Actinic Keratosis through Inhibition of Cyclooxygenase-2: Potential Mechanism of Action of Diclofenac Sodium 3% in Hyaluronic Acid 2.5%","volume":"32","author":"Thomas","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_10","first-page":"851","article-title":"Axillary Basal Cell Carcinoma\u2014A Rare Form of a Frequent Kind of Carcinoma","volume":"54","author":"Costescu","year":"2013","journal-title":"Romanian J. Morphol. Embryol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/TCRM.S12498","article-title":"Diclofenac Gel in the Treatment of Actinic Keratoses","volume":"7","author":"Nelson","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0939-6411(00)00149-1","article-title":"In Vitro Based Index of Topical Anti-Inflammatory Activity to Compare a Series of NSAIDs","volume":"51","author":"Cordero","year":"2001","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/carcin\/bgh076","article-title":"Celecoxib Inhibits Phorbol Ester-Induced Expression of COX-2 and Activation of AP-1 and P38 MAP Kinase in Mouse Skin","volume":"25","author":"Chun","year":"2004","journal-title":"Carcinogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib Pathways: Pharmacokinetics and Pharmacodynamics","volume":"22","author":"Li","year":"2012","journal-title":"Pharm. Genom."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000211314","article-title":"Testing of Lipoxygenase Inhibitors, Cyclooxygenase Inhibitors, Drugs with Immunomodulating Properties and Some Reference Antipsoriatic Drugs in the Modified Mouse Tail Test, an Animal Model of Psoriasis","volume":"7","author":"Bosman","year":"1994","journal-title":"Skin Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2020.04.034","article-title":"Animal Models of Psoriasis\u2014Highlights and Drawbacks","volume":"147","author":"Manzke","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000211016","article-title":"Quantitative Method for Measuring Antipsoriatic Activity of Drugs by the Mouse Tail Test","volume":"5","author":"Bosman","year":"1992","journal-title":"Skin Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.2147\/DDDT.S84849","article-title":"The Relevance of Piroxicam for the Prevention and Treatment of Nonmelanoma Skin Cancer and Its Precursors","volume":"9","author":"Campione","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1080\/03007995.2017.1352497","article-title":"Skin Penetration and Tissue Permeation after Topical Administration of Diclofenac","volume":"33","author":"Hagen","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Szyma\u0144ski, \u0141., Skopek, R., Palusi\u0144ska, M., Schenk, T., Stengel, S., Lewicki, S., Kraj, L., Kami\u0144ski, P., and Zelent, A. (2020). Retinoic Acid and Its Derivatives in Skin. Cells, 9.","DOI":"10.3390\/cells9122660"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08982104.2020.1748646","article-title":"Formulation and Evaluation of a Topical Liposomal Gel Containing a Combination of Zedoary Turmeric Oil and Tretinoin for Psoriasis Activity","volume":"31","author":"Chen","year":"2021","journal-title":"J. Liposome Res."},{"key":"ref_22","first-page":"10","article-title":"The Mechanism of Action of Topical Retinoids","volume":"75","author":"Kang","year":"2005","journal-title":"Cutis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/cr400161b","article-title":"Retinoic Acid Actions Through Mammalian Nuclear Receptors","volume":"114","author":"Huang","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1541-7786.MCR-07-2144","article-title":"Multiple Signaling Pathways Are Responsible for Prostaglandin E2\u2013Induced Murine Keratinocyte Proliferation","volume":"6","author":"Ansari","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_25","first-page":"1277","article-title":"Serum Total Gangliosides Level: Clinical Prognostic Implication","volume":"52","author":"Nicolae","year":"2011","journal-title":"Romanian J. Morphol. Embryol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0022-2275(20)32029-0","article-title":"Prostaglandin E2 Regulation of Cyclooxygenase Expression in Keratinocytes Is Mediated via Cyclic Nucleotide-Linked Prostaglandin Receptors","volume":"41","author":"Maldve","year":"2000","journal-title":"J. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejps.2013.02.009","article-title":"Antiproliferative Effect of Two Novel COX-2 Inhibitors on Human Keratinocytes","volume":"49","author":"Sticozzi","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_28","first-page":"337","article-title":"Gangliosides and Sex Hormones in Human Melanoma","volume":"7","author":"Nicolae","year":"2011","journal-title":"Acta Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1158\/0008-5472.CAN-05-0129","article-title":"The Prostaglandin E2 Receptor EP2 Is Required for Cyclooxygenase 2-Mediated Mammary Hyperplasia","volume":"65","author":"Chang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.brainres.2007.02.023","article-title":"Celecoxib Inhibits Na+ Currents in Rat Dorsal Root Ganglion Neurons","volume":"1148","author":"Park","year":"2007","journal-title":"Brain Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Frolov, R.V., and Singh, S. (2015). Evidence of More Ion Channels Inhibited by Celecoxib: KV1.3 and L-Type Ca2+ Channels. BMC Res. Notes, 8.","DOI":"10.1186\/s13104-015-1023-1"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/885\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:56:12Z","timestamp":1760136972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pharmaceutics14040885"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14040885","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2022,4,18]]}}}